Navenibart Moves Forward in Phase 3 Trial for Hereditary Angioedema Navenibart has entered the phase 3 ORBIT-EXPANSE trial, representing a major advance in the treatment of HAE.

#Navenibart, an investigational long-acting monoclonal antibody against plasma kallikrein, has entered the phase 3 ORBIT-EXPANSE trial, representing a major advance in the treatment of #HereditaryAngioedema (HAE).

Read more: https://bit.ly/3Lbmnmc

#RareDisease #HAE #RareSky #MedSky

#HAE #HereditaryAngioedema #Navenibart #RareDisease #PharmaNews #MedicalInnovation #AstriaTherapeutics #KakenPharmaceutical #ClinicalTrials #BioNews #AngioedemaNews

#Angioedema #HAE #ClinicalTrials #RareDisease #Navenibart #ResearchProgress #AngioedemaNews #Bionews @astriatx